- Home
- BEN vs ROIV Comparison
BEN vs ROIV Comparison
Compare BEN & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEN
- ROIV
- Stock Information
- Founded
- BEN 1947
- ROIV 2014
- Country
- BEN United States
- ROIV United Kingdom
- Employees
- BEN N/A
- ROIV N/A
- Industry
- BEN Investment Managers
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- BEN Finance
- ROIV Health Care
- Exchange
- BEN Nasdaq
- ROIV Nasdaq
- Market Cap
- BEN 12.1B
- ROIV 14.0B
- IPO Year
- BEN N/A
- ROIV N/A
- Fundamental
- Price
- BEN $23.03
- ROIV $21.25
- Analyst Decision
- BEN Hold
- ROIV Strong Buy
- Analyst Count
- BEN 11
- ROIV 8
- Target Price
- BEN $23.05
- ROIV $21.19
- AVG Volume (30 Days)
- BEN 4.2M
- ROIV 9.2M
- Earning Date
- BEN 11-07-2025
- ROIV 11-10-2025
- Dividend Yield
- BEN 5.55%
- ROIV N/A
- EPS Growth
- BEN 7.28
- ROIV N/A
- EPS
- BEN 0.91
- ROIV N/A
- Revenue
- BEN $8,770,700,000.00
- ROIV $20,329,000.00
- Revenue This Year
- BEN N/A
- ROIV N/A
- Revenue Next Year
- BEN $5.20
- ROIV $320.50
- P/E Ratio
- BEN $25.33
- ROIV N/A
- Revenue Growth
- BEN 3.45
- ROIV N/A
- 52 Week Low
- BEN $16.25
- ROIV $8.73
- 52 Week High
- BEN $26.08
- ROIV $21.35
- Technical
- Relative Strength Index (RSI)
- BEN 51.04
- ROIV 81.45
- Support Level
- BEN $21.50
- ROIV $19.79
- Resistance Level
- BEN $23.39
- ROIV $21.35
- Average True Range (ATR)
- BEN 0.54
- ROIV 0.72
- MACD
- BEN 0.05
- ROIV 0.08
- Stochastic Oscillator
- BEN 71.73
- ROIV 97.11
About BEN Franklin Resources Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of July 2025, Franklin had $1.617 trillion in managed assets, composed primarily of equity (41%), fixed-income (27%), multi-asset/balanced (11%) funds, alternatives (16%) and money market funds (5%). Distribution tends to be weighted between retail investors (56% of AUM) and institutional accounts (41%), with high-net-worth clients accounting for the remainder. Franklin is one of the more global of the US-based asset managers we cover, with 31% of its assets under management invested in global/international strategies and just as much sourced from clients domiciled outside the United States.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.